Hudson Bay Capital Management LP Trims Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Hudson Bay Capital Management LP trimmed its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 22.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 499,700 shares of the biopharmaceutical company's stock after selling 140,900 shares during the quarter. Hudson Bay Capital Management LP owned about 0.38% of Dynavax Technologies worth $6,381,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. E Fund Management Co. Ltd. raised its position in shares of Dynavax Technologies by 4.6% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company's stock valued at $225,000 after purchasing an additional 771 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Dynavax Technologies by 7.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock worth $176,000 after purchasing an additional 904 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 1,076 shares during the period. Sanctuary Advisors LLC grew its stake in shares of Dynavax Technologies by 6.3% during the 4th quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock worth $245,000 after purchasing an additional 1,109 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 1,169 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DVAX has been the topic of a number of research analyst reports. JMP Securities dropped their price target on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. StockNews.com lowered Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, The Goldman Sachs Group reduced their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Dynavax Technologies presently has a consensus rating of "Hold" and an average target price of $24.00.

Dynavax Technologies Stock Up 1.7%

NASDAQ DVAX traded up $0.16 on Friday, hitting $9.67. 1,573,605 shares of the stock were exchanged, compared to its average volume of 2,222,197. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a fifty-two week low of $9.22 and a fifty-two week high of $14.63. The company has a market cap of $1.16 billion, a PE ratio of 53.72 and a beta of 1.26. The company has a 50-day moving average price of $11.78 and a 200-day moving average price of $12.51.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). The company had revenue of $68.16 million for the quarter, compared to analysts' expectations of $70.01 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Sell-side analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.